Drugs / 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
4-Demethyl-4-cholesteryloxycarbonylpenclomedine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03371004 | Feb 2016 → Oct 2022 | cancer of unknown primary site | DEKK-TEC, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01976910 | Sep 2010 → Oct 2013 | — | DEKK-TEC, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01048008 | Sep 2010 → Jul 2013 | brain neoplasm, cancer of unknown primary site | DEKK-TEC, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03668847 | Jan 2019 → Aug 2021 | cancer of unknown primary site, metastatic malignant neoplasm in the brain | DEKK-TEC, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02889445 | — | cancer of unknown primary site | DEKK-TEC, Inc. | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-Demethyl-4-cholesteryloxycarbonylpenclomedine | “4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood...” NCT03668847 ↗ |
| Known as | DM-CHOC-PEN | “4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood...” NCT03371004 ↗ |
| Known as | Mipicoledine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297253 ↗ |
| Modality | Other / unclassified | “is a polychlorinated pyridyl cholesterol carbonate” NCT03371004 ↗ |
| Modality | Small molecule | — CHEMBL4297253 ↗ |
| Route | Intravenous | “administered intravenously” NCT01048008 ↗ |